|
News & Information |
|
Prostate / Prostate Cancer News From Medical News Today
|
Latest Prostate / Prostate Cancer News From Medical News Today.
|
-
Dendreon Expects Interim Data Analysis For Phase 3 PROVENGE IMPACT Trial In October
Dendreon Corporation (Nasdaq: DNDN) announced that it expects the Independent Data Monitoring Committee (IDMC) to review in October 2008 the interim analysis of overall survival relating to the Company's Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T). PROVENGE is the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer.
-
Transurethral Resection Of The Prostate Role In Patients With Elevated PSA Level, Minor Lower Urinary Tract Symptoms, And Bladder Outlet Obstruction
UroToday.com - In the online edition of European Urology, Dr. Koenraad van Renterghem and associates presented their data on how to manage patients with an elevated PSA and proven bladder outlet obstruction. Between 2005 and 2007, 33 consecutive men with an elevated PSA, a negative prostate biopsy, minor LUTS (IPSS 0-19), and with urodynamics evidence of bladder outlet obstruction all underwent a transurethral resection of the prostate (TURP). The mean patient age was 66.
-
Partial Salvage Cryoablation Of The Prostate For Recurrent Prostate Cancer After Radiotherapy Failure
UroToday.com - In the online edition of Urology, Drs. Michael Eisenberg and Katsuto Shinohara reported on their experience using partial (unilobar) cryotherapy for patients with a local recurrence of prostate cancer (CaP) following radiotherapy (XRT). Between 2004 and 2007, 19 patients had failed XRT by either the ASTRO or Phoenix criteria. All had 16-core prostate biopsies performed to document recurrence, and metastatic evaluations were negative.
-
Visualisation Software To Aid Prostate Cancer Detection
Visualisation specialists See3D, a spin off company of the University of Aberystwyth, is developing unique, sophisticated computer-generated models that will help doctors to improve the diagnosis and treatment of prostate cancer. More than 35,000 men are diagnosed with prostate cancer each year in the UK alone and approximately 10,000 deaths per year are associated with this form of cancer.
-
Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme In Prostate Cancer Models
Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, announced the presentation of positive pre-clinical animal efficacy data for its pegylated-rHuPH20 enzyme (PEGPH20) at the American Association for Cancer Research (AACR) Translational Cancer Medicine meeting in Monterey, CA.
-
Prostate Cancer Drug Breakthrough For Aggressive Form Of Disease
A new trial drug called abiraterone has shown a high success rate at treating men with an aggressive, drug resistant, and often fatal form of prostate cancer. 70 to 80 per cent of the men on the trial experienced dramatic reductions in PSA (a protein marker for prostate cancer) and tumour shrinkage, even in tumours that had spread to bone and other tissue.
-
New Gene Combination May Cause Deadly Prostate Cancer
Scientists at The Institute of Cancer Research have found that the partnering of two genes could be responsible for up to 600 British men developing a drug resistant and potentially deadly form of prostate cancer each year. The international study, published in the British Journal of Cancer, also outlines the discovery of a new prostate cancer gene, ACSL3.
-
Amgen Announces Positive Top-Line Results For Denosumab Treatment Of Bone Loss In Men With Non-Metastatic Prostate Cancer
Amgen (NASDAQ:AMGN) announced findings from a three-year pivotal Phase 3 placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer.
-
Impact Of Surgical Volume On The Rate Of Lymph Node Metastases In Patients Undergoing Radical Prostatectomy
UroToday.com - In this online publication by Dr. Alberto Briganti and associates that appears in European Urology, the authors hypothesized that surgical volume (SV) is related to the detection rate of lymph node invasion (LNI) in a single-institution cohort of men treated with radical prostatectomy (RP) and extended pelvic lymph node dissection (ePLND).
-
Association Between Serum Prostate-Specific Antigen Level, Liver Function Tests And Lipid Profile In Healthy Men
UroToday.com - In the online version of the BJU International, a group of Korean investigators has reported on the impact of liver function and lipid parameters on PSA levels. The liver is involved in eliminating serum PSA, but the kidneys and lungs are not. Free PSA is eliminated by the kidneys, but due to its molecular size, PSA bound to larger proteins is cleared through the liver. Furthermore, the lipid profile can affect serum PSA levels through the metabolism of serum testosterone.
|
|
News & Information 
